We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Aclaris Therapeutics Inc | NASDAQ:ACRS | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.01 | -0.82% | 1.21 | 1.21 | 1.22 | 1.23 | 1.19 | 1.19 | 360,696 | 17:43:57 |
From Apr 2019 to Apr 2024
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a physician-led biopharmaceutical company committed to addressing the needs of people with dermatological and immuno-inflammatory diseases who lack satisfactory treatment options. The company’s diverse and multi-stage portfolio includes two FDA-approved medicines, one late-stage investigational medicine, and a pipeline powered by a robust R&D engine exploring protein kinase regulation. Aclaris Therapeutics’ active development programs focus on areas where significant treatment gaps exist, such as common warts, alopecia areata, and vitiligo. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn or Twitter @aclaristx.
Contact:
Aclaris ContactMichael Tung, M.D.Senior Vice President Corporate Strategy/Investor Relations484-329-2140mtung@aclaristx.com
Media ContactSheila KennedyVice President, Corporate Communications484-321-5559media@aclaristx.com
1 Year Aclaris Therapeutics Chart |
1 Month Aclaris Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
